AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TELIX PHARMACEUTICALS LTD

15.620

-1.760-10.13%

Volume:4.59M

Turnover:73.40M

Market Cap:5.29B

PE:-530.19

High:16.760

Open:16.620

Low:15.620

Close:17.380

52wk High:19.070

52wk Low:8.260

Shares:338.72M

Float Shares:275.41M

Volume Ratio:2.07

T/O Rate:1.67%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.029

EPS(LYR):-0.029

ROE:7.36%

ROA:2.71%

PB:7.77

PE(LYR):-530.19

Loading ...

Overview Company News Filings

ASX Growth Companies With Insider Ownership Up To 38%

Simply Wall St.

Heidelberg Pharma FY2025 annual report published; net loss widens to EUR -42 million

How I'd invest $20,000 in ASX shares right now to help build long-term wealth

A Look At Telix Pharmaceuticals (ASX:TLX) Valuation After Key TLX101-Px And TLX591-Tx Trial Updates

Simply Wall St.

3 top ASX shares that could double in value from here

These are the 10 most shorted ASX shares

Bell Potter says these ASX 200 stocks could rise 50%+

Telix Pharmaceuticals (ASX:TLX) Is Up 12.9% After TLX101-Px NDA Resubmission and U.S. Build-Out News – Has The Bull Case Changed?

Simply Wall St.

BRIEF-Telix Selects IBA's Cyclone® Kiube To Support Manufacturing Expansion In US

IBA signs contract with Telix for four Cyclone KIUBE cyclotrons in the U.S

Telix Pharmaceuticals Says Citigroup Lifts Stake

MT Newswires Live

Stock Track | Telix Pharmaceuticals Soars 5.04% Intraday on FDA Resubmission and Strong Growth Prospects

Could Telix shares be a millionaire-maker stock?

Telix Pharmaceuticals Ltd. files Form 3 initial beneficial ownership statement for director Jann Elizabeth Skinner

Telix Pharmaceuticals Ltd. files Form 3 initial beneficial ownership statement for MD and Group CEO Christian Behrenbruch

Here are the top 10 ASX 200 shares today

3 ASX healthcare stocks tipped to soar over 100% higher this year

Why are Telix shares racing 8% higher today?

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/TLX.AU/news?page=10"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"TLX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","market":"AU","secType":"STK","nameCN":"TELIX PHARMACEUTICALS LTD","latestPrice":15.62,"timestamp":1787292720000,"preClose":17.38,"halted":0,"volume":4587381,"delay":0,"changeRate":-0.10126582278481013,"nameEN":"TELIX PHARMACEUTICALS LTD","floatShares":275410996,"shares":338721355,"eps":-0.029466146051536427,"marketStatus":"Not Yet Opened","change":-1.76,"latestTime":"08-21 16:12:00 AEST","open":16.62,"high":16.76,"low":15.62,"amount":73404620,"amplitude":0.065593,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.029466146051536427,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787529600000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":17.38,"openAndCloseTimeList":[[1787270400000,1787292000000]],"volumeRatio":2.071427752114666,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"TLX.AU","preClose":15.62,"auctionPrice":15.6,"auctionVolume":2871,"auctionTime":1787518872158,"referenceTime":1787308204093,"auction":1,"marketStatus":"盘前竞价","timestamp":1787518872158}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","floatShares":275410996,"roa":"2.71%","roe":"7.36%","lyrEps":-0.029461,"volumeRatio":2.071427752114666,"shares":338721355,"dividePrice":0,"high":16.76,"amplitude":0.065593,"preClose":17.38,"low":15.62,"week52Low":8.26,"pbRate":"7.77","psRate":"4.25","week52High":19.07,"institutionHeld":0,"latestPrice":15.62,"eps":-0.029461208942803362,"divideRate":0,"volume":4587381,"delay":0,"ttmEps":-0.029461208942803362,"open":16.62,"prevYearClose":11.2,"prevWeekClose":15.62,"prevMonthClose":14.21,"prevQuarterClose":16.58,"fiveDayClose":16.73,"twentyDayClose":14.66,"sixtyDayClose":13.03},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-20","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787184000000,"name":null,"time":"","dateTimestamp":1787148000000,"actualEps":null},{"date":"2026-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1771455600000,"name":null,"time":"","dateTimestamp":1771419600000,"actualEps":null},{"date":"2026-01-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1768777200000,"name":null,"time":"","dateTimestamp":1768741200000,"actualEps":null},{"date":"2025-08-21","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755734400000,"name":null,"time":"","dateTimestamp":1755698400000,"actualEps":null},{"date":"2025-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1739919600000,"name":null,"time":"","dateTimestamp":1739883600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX.AU\",pageSize:20,pageCount:10,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622895939","title":"ASX Growth Companies With Insider Ownership Up To 38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622895939","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622895939?lang=en_us&edition=fundamental","pubTime":"2026-03-27 03:08","pubTimestamp":1774552107,"startTime":"0","endTime":"0","summary":"As the Australian stock market experiences a modest rise amidst geopolitical uncertainties, investors are keeping a close watch on sectors poised for growth and resilience. In such an environment, companies with high insider ownership often attract attention due to the confidence they signal in their own potential, making them intriguing prospects for those seeking long-term growth opportunities.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6033000-choice1-main-header/1585186824821","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6033000-choice1-main-header/1585186824821"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-reg/regis-healthcare-shares/news/asx-growth-companies-with-insider-ownership-up-to-38-2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-reg/regis-healthcare-shares/news/asx-growth-companies-with-insider-ownership-up-to-38-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7129","TOR.AU","AEM.AU","BK7104","EIQ.AU","BK7095","MAU.AU","FRS.AU","AR1.AU","BK7508","REG.AU","BK4531","CYC.AU","BK4526","IQ","BK7007","BK4139","BK7067","BK4108","TLX.AU","TLX","FEX.AU","BK4505","CUV.AU","BK7113","BK4552","BK7110","BK7016","AV1.AU","BK7017"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622836040","title":"Heidelberg Pharma FY2025 annual report published; net loss widens to EUR -42 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622836040","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622836040?lang=en_us&edition=fundamental","pubTime":"2026-03-26 14:53","pubTimestamp":1774508032,"startTime":"0","endTime":"0","summary":"Heidelberg Pharma’s annual report outlines a strategic refocus on its lead Amanitin-based ADC program HDP-101 after a delayed milestone tied to Telix’s TLX250-Px, which received an FDA Complete Response Letter citing CMC comparability and third-party manufacturing deficiencies.Clinical updates include continued dose escalation for HDP-101 in relapsed or refractory multiple myeloma, with an objective response rate of 57% reported in cohort 8 at 140 g/kg and Fast Track designation granted by the FDA.Business development highlights include a March 2025 amendment to the HealthCare Royalty agreement that provided an upfront payment of USD 20 million and the start of clinical development by partner Takeda for an ATAC candidate after the reporting period.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should n","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL6QP1pl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622001389","title":"How I'd invest $20,000 in ASX shares right now to help build long-term wealth","url":"https://stock-news.laohu8.com/highlight/detail?id=2622001389","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622001389?lang=en_us&edition=fundamental","pubTime":"2026-03-26 03:15","pubTimestamp":1774466100,"startTime":"0","endTime":"0","summary":"Putting $20,000 to work in the market is a meaningful step. At that size, I'd be thinking about building a portfolio that can grow through different conditions.For me, that means combining quality, growth, and a bit of resilience.Here's why I would split the money across these four names.Hub24 continues to build momentum in a way that's hard to ignore.It operates a wealth management platform that continues to attract funds from advisers and clients moving toward more sophisticated investment solutions.What stands out to me is its ability to consistently grow funds under administration. That kind of growth can compound over time, especially as the shift toward managed platforms continues.It's an ASX share that I think could look significantly larger in a decade than it does today.James Hardie Industries brings exposure to global construction and housing.That might sound cyclical, and it is, but James Hardie has built a strong position in fibre cement products, particularly in the United","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/26/how-id-invest-20000-in-asx-shares-right-now-to-help-build-long-term-wealth-2/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/26/how-id-invest-20000-in-asx-shares-right-now-to-help-build-long-term-wealth-2/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["TLX.AU","BK7511","HUB.AU","BK7067","BK7507","BK7054","BK7044","JHX.AU","BHP.AU","BK7095"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621507720","title":"A Look At Telix Pharmaceuticals (ASX:TLX) Valuation After Key TLX101-Px And TLX591-Tx Trial Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2621507720","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621507720?lang=en_us&edition=fundamental","pubTime":"2026-03-23 12:27","pubTimestamp":1774240038,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) has entered a busy regulatory phase, resubmitting its TLX101-Px New Drug Application for glioma imaging while also reporting that the lead-in stage of its TLX591-Tx Phase 3 prostate cancer trial met safety objectives.\nSee our latest analysis for Telix Pharmaceuticals.\nThese regulatory updates come after a strong short term run, with a 1 month share price return of 22.24% and a 7 day share price return of 12.93%. However, the 1 year total shareholder return is...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/a-look-at-telix-pharmaceuticals-asxtlx-valuation-after-key-t","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/a-look-at-telix-pharmaceuticals-asxtlx-valuation-after-key-t","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","TLX","TLX.AU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621744550","title":"3 top ASX shares that could double in value from here","url":"https://stock-news.laohu8.com/highlight/detail?id=2621744550","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621744550?lang=en_us&edition=fundamental","pubTime":"2026-03-23 06:27","pubTimestamp":1774218446,"startTime":"0","endTime":"0","summary":"It's been a rough stretch for some of the most talked-about ASX shares. But here's the twist: while share prices have slid or stalled, broker optimism hasn't. In fact, it's surging.Three ASX shares stand out right now: Mesoblast Ltd , Telix Pharmaceuticals Ltd , and Zip Co Ltd . All three have had turbulent months. Yet analysts see massive upside, in some cases, more than a double from here.This ASX share has had a shaky start to the year, with the share price down about 25%. That's nothing new for this high-risk biotech stock. Volatility comes with the territory.Analyst outlook: This is where things get interesting. Brokers have an average price target on the ASX share of $4.23 at the time of writing. That implies around 105% upside. In other words, analysts believe a doubling is firmly on the table if execution improves.Analyst outlook: Despite all that, brokers are highly optimistic. The average price target is $4.21. That's about 191% upside — nearly triple its current share price.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/23/3-top-asx-shares-that-could-double-in-value-from-here/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/23/3-top-asx-shares-that-could-double-in-value-from-here/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["TLX.AU","MSB.AU","BK7093","BK7501","ZIP.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621774129","title":"These are the 10 most shorted ASX shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2621774129","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621774129?lang=en_us&edition=fundamental","pubTime":"2026-03-23 05:54","pubTimestamp":1774216455,"startTime":"0","endTime":"0","summary":"At the start of each week, I like to look atASIC's short position reportto find out which shares are being targeted by short sellers.This is because I believe it is well worth keeping a close eye on short interest levels as high levels can sometimes be a sign that something isn't quite right with a company.With that in mind, here are the 10 most shorted shares on the ASX this week according to ASIC:. Domino's Pizza Enterprises Ltd  continues to be the most shorted ASX share with short interest of 16%. This is up week on week. Short sellers appear doubtful that the struggling pizza chain operator's turnaround strategy will be a success.Treasury Wine Estates Ltd  has seen its short interest rise again to 15.1%. This wine giant has been battling very tough trading conditions, with consumers focusing on value rather than its premium wines.Flight Centre Travel Group Ltd  has short interest of 10.3%, which is up week on week. There are concerns that the travel agent won't deliver on its reve","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/23/these-are-the-10-most-shorted-asx-shares-23-march-2026/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/23/these-are-the-10-most-shorted-asx-shares-23-march-2026/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7132","BK7067","IEL.AU","BK7095","LYC.AU","FLT.AU","TWE.AU","DMP.AU","GYG.AU","BOE.AU","TLX.AU","BK7508","PNV.AU","BK7507","BK7083","BK7070","BK7137","BK7097","BK7505","NAN.AU","BK7126","BK7503"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621792517","title":"Bell Potter says these ASX 200 stocks could rise 50%+","url":"https://stock-news.laohu8.com/highlight/detail?id=2621792517","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621792517?lang=en_us&edition=fundamental","pubTime":"2026-03-22 06:33","pubTimestamp":1774132380,"startTime":"0","endTime":"0","summary":"If you are looking to add some ASX 200 stocks to your portfolio this week, it could be worth checking out the two in this article. That's because Bell Potter believes they could be dirt cheap at curre","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/22/bell-potter-says-these-asx-200-stocks-could-rise-50/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/22/bell-potter-says-these-asx-200-stocks-could-rise-50/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7094","BK7067","PME.AU","TLX.AU","BLA.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621183756","title":"Telix Pharmaceuticals (ASX:TLX) Is Up 12.9% After TLX101-Px NDA Resubmission and U.S. Build-Out News – Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2621183756","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621183756?lang=en_us&edition=fundamental","pubTime":"2026-03-21 01:13","pubTimestamp":1774026782,"startTime":"0","endTime":"0","summary":"In March 2026, Telix Pharmaceuticals resubmitted its New Drug Application to the FDA for TLX101-Px (Pixclara), an investigational PET imaging agent for distinguishing recurrent or progressive glioma from treatment-related changes in adults and children, incorporating additional data requested after a prior Complete Response Letter and supported by Orphan Drug and Fast Track designations.\nA key differentiator is that 18F-FET imaging like TLX101-Px is already referenced in international glioma...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-asxtlx-is-up-129-after-tlx101-px-nda-r","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-asxtlx-is-up-129-after-tlx101-px-nda-r","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TLX.AU","TLX","BK7067","BK4139","BGSX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620207966","title":"BRIEF-Telix Selects IBA's Cyclone® Kiube To Support Manufacturing Expansion In US","url":"https://stock-news.laohu8.com/highlight/detail?id=2620207966","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620207966?lang=en_us&edition=fundamental","pubTime":"2026-03-20 14:03","pubTimestamp":1773986631,"startTime":"0","endTime":"0","summary":"BRIEF-Telix Selects IBA's Cyclone Kiube To Support Manufacturing Expansion In USMarch 20 (Reuters) - Ion Beam Applications SA IBAB.BR:REG-TELIX SELECTS IBA CYCLONE KIUBE TO SUPPORT MANUFACTURING EXPAN","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nFWN4071AD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620344207","title":"IBA signs contract with Telix for four Cyclone KIUBE cyclotrons in the U.S","url":"https://stock-news.laohu8.com/highlight/detail?id=2620344207","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620344207?lang=en_us&edition=fundamental","pubTime":"2026-03-20 13:58","pubTimestamp":1773986306,"startTime":"0","endTime":"0","summary":"IBA signed a contract with Telix for an initial order of four Cyclone KIUBE cyclotrons to be installed at select RLS Radiopharmacies sites in the U.S.Each system will be equipped with the ARTMS QUANTM Irradiation System.The equipment is intended to support cGMP-compliant production of isotopes including Gallium-68 and Zirconium-89.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IBA - Ion Beam Applications SA published the original content used to generate this news brief on March 20, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDL6llHQ3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620202561","title":"Telix Pharmaceuticals Says Citigroup Lifts Stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2620202561","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620202561?lang=en_us&edition=fundamental","pubTime":"2026-03-20 13:17","pubTimestamp":1773983826,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) received notice that Citigroup and its affiliates increased their holdings in the company to 6.0668% from 5.0639%, according to a Friday filing with the Australian bourse.Citigroup and its affiliates now own 20.6 million shares in the company, the filing said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","TLX.AU","TLX","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136813239","title":"Stock Track | Telix Pharmaceuticals Soars 5.04% Intraday on FDA Resubmission and Strong Growth Prospects","url":"https://stock-news.laohu8.com/highlight/detail?id=1136813239","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136813239?lang=en_us&edition=fundamental","pubTime":"2026-03-20 09:30","pubTimestamp":1773970232,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Ltd (ASX: TLX) saw its shares soar 5.04% during intraday trading on Friday, marking a significant upward movement for the biopharmaceutical company.The surge follows the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620226319","title":"Could Telix shares be a millionaire-maker stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2620226319","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620226319?lang=en_us&edition=fundamental","pubTime":"2026-03-19 21:30","pubTimestamp":1773927000,"startTime":"0","endTime":"0","summary":"It's been a wild ride for investors in Telix Pharmaceuticals Ltd  shares. The biotech star surged to a high of $29.72 nearly a year ago, only to tumble around 56% to $12.29 at the time of writing.That kind of volatility might scare some investors away. But for others, it raises a more intriguing question: Could Telix shares become a long-term winner and turn $50,000 into a $1,000,000?Importantly, Telix has already transitioned into full commercial operations. That sets it apart from many speculative biotech plays still waiting on approvals.As more of its products gain regulatory clearance and clinical adoption increases, revenue has the potential to scale rapidly. In other words, future growth is less about macroeconomic conditions and more about how quickly its therapies are adopted.This week, Telix resubmitted its New Drug Application to the U.S. FDA for TLX101-Px, including new data addressing prior feedback and supporting approval.According to TradingView data, all 16 analysts cove","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/20/could-telix-shares-be-a-millionaire-maker-stock/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/20/could-telix-shares-be-a-millionaire-maker-stock/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620929148","title":"Telix Pharmaceuticals Ltd. files Form 3 initial beneficial ownership statement for director Jann Elizabeth Skinner","url":"https://stock-news.laohu8.com/highlight/detail?id=2620929148","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620929148?lang=en_us&edition=fundamental","pubTime":"2026-03-19 08:47","pubTimestamp":1773881275,"startTime":"0","endTime":"0","summary":"Telix reported an initial statement of beneficial ownership by director Jann Elizabeth Skinner dated 03/18/2026. Skinner reported indirect beneficial ownership of 595,000 ordinary shares. The shares were held through Forellan Pty Limited.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL3VRRyJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620291104","title":"Telix Pharmaceuticals Ltd. files Form 3 initial beneficial ownership statement for MD and Group CEO Christian Behrenbruch","url":"https://stock-news.laohu8.com/highlight/detail?id=2620291104","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620291104?lang=en_us&edition=fundamental","pubTime":"2026-03-19 08:46","pubTimestamp":1773881194,"startTime":"0","endTime":"0","summary":"Telix reported an initial statement of beneficial ownership by Christian Behrenbruch, who is a director and MD and Group CEO. Behrenbruch reported indirect beneficial ownership of 20.68 million ordinary shares. He also reported direct beneficial ownership of 400,000 American Depositary Receipts and 254,006 ordinary shares. Behrenbruch reported derivative holdings including performance share appreciation rights covering 93,114 ordinary shares at an exercise price of AUD 4,950. He also reported performance share appreciation rights covering 100,223 ordinary shares at an exercise price of AUD 6,900.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief via","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL8MX89G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620284355","title":"Here are the top 10 ASX 200 shares today","url":"https://stock-news.laohu8.com/highlight/detail?id=2620284355","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620284355?lang=en_us&edition=fundamental","pubTime":"2026-03-18 13:55","pubTimestamp":1773813328,"startTime":"0","endTime":"0","summary":"The S&P/ASX 200 Index (ASX: XJO) enjoyed another mild recovery day this hump day, adding to yesterday's modest rise. After a brief dip into negative territory this morning, the ASX 200 spent the rest ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/18/here-are-the-top-10-asx-200-shares-today-18-march-2026/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/18/here-are-the-top-10-asx-200-shares-today-18-march-2026/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["VEA.AU","DGT.AU","BK7067","BK7021","PMV.AU","ILU.AU","XJO.AU","WEB.AU","ASB.AU","BK7083","BK7095","BK7065","BK7115","BK7166","BK7070","SGM.AU","BK7129","TLX.AU","DRO.AU","NHC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620818702","title":"3 ASX healthcare stocks tipped to soar over 100% higher this year","url":"https://stock-news.laohu8.com/highlight/detail?id=2620818702","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620818702?lang=en_us&edition=fundamental","pubTime":"2026-03-18 12:59","pubTimestamp":1773809940,"startTime":"0","endTime":"0","summary":"ASX healthcare stocks are a popular option for investors seeking defensive assets with long-term structural growth.These shares can offer portfolio diversification, drive high margins, and some of them have huge potential upside.Here are three ASX healthcare stocks on my radar this week, and analysts are tipping upside well over 100% over the next 12 months.The beaten-down medical imaging technology stock has dropped another 1.7% in Wednesday afternoon trade, to $125.69 a piece. The decline is part of a long string of declines off the back of sector-wide headwinds, which have seen the share price crash 62% from an all-time high recorded in mid-2025.Sentiment didn't improve when the company posted a record-breaking half-year FY26 result in mid-February. Its revenue was up 28%, and profit jumped nearly 30%, but it still missed investors' high expectations.Analysts are excited about the prospects for growth of the ASX healthcare stock's business fundamentals and share price over the next ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/18/3-asx-healthcare-stocks-tipped-to-soar-over-100-higher-this-year/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/18/3-asx-healthcare-stocks-tipped-to-soar-over-100-higher-this-year/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7067","TLX.AU","BK7094","CU6.AU","BK7096","PME.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620407297","title":"Why are Telix shares racing 8% higher today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2620407297","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620407297?lang=en_us&edition=fundamental","pubTime":"2026-03-18 09:20","pubTimestamp":1773796840,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Ltd  shares are racing higher in Wednesday morning trade. At the time of writing the biopharmaceutical company's shares are up 8% to $12.58 a piece. The uptick now means the shares are 11% higher for the year-to-date and have recovered some losses seen during the sharp selloff throughout 2025. Telix shares are now 54% lower than this time last year. Image source: Getty Images What happened to Telix shares?Telix shares are now widely considered oversold and undervalued. Analysts are very bullish on where the share price can go from here. TradingView data shows that all 16 analysts have a buy or strong buy rating on the stock. And the expectation among all of them is that the share price will fly higher over the next 12 months. Some expect the shares to climb 92% to $23.97, but others are even more optimistic and expect the share price to rocket to $31.59 a piece over the next 12 months. That implies an enormous 154% upside, at the time of writing.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/18/why-are-telix-shares-racing-8-higher-today/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/18/why-are-telix-shares-racing-8-higher-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":10,"totalSize":198,"code":"91000000","status":"200"}]}}